• Explore /
  • Poster
  • / A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.

A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.

Abstract Poster

Authors

null

Yu Pengfei

Zhejiang Cancer Hospital (University of Chinese Academy of Sciences Cancer Hospital), Hangzhou, China

Yu Pengfei , Yian Du , Zhiyuan Xu , Litao Yang , Jieer Ying , Yongxiang Wang , Ping Chen , Yunhai Wei , Hongtao Xu , Nong Xu , Xiangdong Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT04135781

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4052)

DOI

10.1200/JCO.2022.40.16_suppl.4052

Abstract #

4052

Poster Bd #

40

Abstract Disclosures

Similar Posters

First Author: Yoshiaki Nakamura

Poster

2016 Gastrointestinal Cancers Symposium

“Real world” effectiveness of different postoperative adjuvant chemotherapy regimens in stage III colon cancer patients.

“Real world” effectiveness of different postoperative adjuvant chemotherapy regimens in stage III colon cancer patients.

First Author: Jy Ming Chiang

First Author: Yu Pengfei

First Author: Yu Pengfei